First Bluesky post - a BIG update to our study on Ewing sarcoma and other FET fusion-driven cancers. FET fusion oncoproteins are aberrantly recruited to DNA breaks and cause ATM defects, which can be targeted with the ATR inhibitor elimusertib. Updates include: www.biorxiv.org/content/10.1...